# Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

> **NCT03572491** · PHASE3 · COMPLETED · sponsor: **Research Institute for Biological Safety Problems** · enrollment: 2000 (actual)

## Conditions studied

- Human Influenza

## Interventions

- **BIOLOGICAL:** influenza vaccine

## Key facts

- **NCT ID:** NCT03572491
- **Lead sponsor:** Research Institute for Biological Safety Problems
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-05-21
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2018-06-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572491, "Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03572491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*